Skip to main content
. 2003 Feb 15;326(7385):388–392. doi: 10.1136/bmj.326.7385.388

Figure 2.

Figure 2

Risk of progression of disability at about two years. Numbers were obtained from a systematic review of interferon beta in relapsing-remitting multiple sclerosis5 as well as individual trials. There was no statistical heterogeneity between individual trials contributing to summary statistics